Zymeworks Valuation

Is ZA8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZA8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZA8's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZA8's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZA8?

Other financial metrics that can be useful for relative valuation.

ZA8 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.2x
Enterprise Value/EBITDA-1.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ZA8's PS Ratio compare to its peers?

The above table shows the PS ratio for ZA8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.3x
FYB Formycon
9.8x26.1%€762.9m
BIO3 Biotest
1.7x2.0%€1.4b
HPHA Heidelberg Pharma
15.3x28.7%€138.9m
MOR MorphoSys
10.5x21.6%€2.5b
ZA8 Zymeworks
13x16.6%€655.7m

Price-To-Sales vs Peers: ZA8 is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (9.3x).


Price to Earnings Ratio vs Industry

How does ZA8's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: ZA8 is expensive based on its Price-To-Sales Ratio (13x) compared to the European Biotechs industry average (9.7x).


Price to Sales Ratio vs Fair Ratio

What is ZA8's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZA8 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13x
Fair PS Ratio0.2x

Price-To-Sales vs Fair Ratio: ZA8 is expensive based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZA8 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.30
€12.75
+53.6%
25.3%€18.58€9.29n/a9
Apr ’25€9.49
€12.97
+36.6%
26.1%€19.22€9.15n/a9
Mar ’25€11.07
€12.33
+11.4%
28.2%€17.64€7.43n/a9
Feb ’25€10.01
€12.18
+21.7%
27.8%€17.31€7.29n/a10
Jan ’25€9.49
€12.18
+28.3%
27.8%€17.31€7.29n/a10
Dec ’24€8.15
€12.65
+55.2%
26.4%€17.78€7.49n/a11
Nov ’24€6.51
€12.43
+90.9%
27.5%€17.47€7.36n/a11
Oct ’24€5.80
€12.43
+114.2%
27.5%€17.47€7.36n/a11
Sep ’24€6.57
€12.43
+89.3%
27.5%€17.47€7.36n/a11
Aug ’24€6.66
€12.30
+84.7%
28.0%€17.18€7.23n/a11
Jul ’24€7.71
€12.72
+65.1%
28.0%€17.76€7.48n/a11
Jun ’24€7.56
€12.63
+67.1%
28.0%€17.64€7.43n/a11
May ’24€7.54
€12.34
+63.5%
26.8%€16.96€7.34€7.6511
Apr ’24€8.68
€12.34
+42.1%
26.8%€16.96€7.34€9.4911
Mar ’24n/a
€12.80
0%
30.5%€19.59€7.46€11.0711
Feb ’24n/a
€12.38
0%
32.6%€19.33€7.36€10.0111
Jan ’24€7.17
€12.09
+68.6%
34.0%€19.78€7.54€9.4912
Dec ’23€7.31
€12.02
+64.4%
39.1%€20.50€6.83€8.1512
Nov ’23€7.26
€13.26
+82.7%
44.7%€24.30€7.09€6.5112
Oct ’23€5.35
€21.03
+293.1%
52.7%€45.11€7.02€5.8012
Sep ’23n/a
€21.55
0%
52.0%€45.16€7.02€6.5712
Aug ’23n/a
€23.43
0%
39.5%€42.02€13.07€6.6611
Jul ’23€5.51
€23.43
+325.2%
39.5%€42.02€13.07€7.7111
Jun ’23€6.58
€23.72
+260.4%
37.5%€41.93€13.05€7.5611
May ’23€7.10
€26.77
+277.1%
35.9%€41.69€13.90€7.5410

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.